Payment overview · 2025
General Payments
$265.52
16 reported records · 8 companies
Healthcare provider profile · identity verified
John C Dunham, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CLARKSVILLE, AR · NPI 1487624896
Verified facts
What the public records show
CMS Open Payments records show John C Dunham, M.D. received $265.52 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.64 | 24.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.22 | 22.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.77 | 19.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.26 | 14.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.30 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.29 | 6.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.16 | 5.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $2.88 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $265.52 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.22 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| JADA SYSTEM Normalized: jada system |
Device | Organon LLC | $2.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
116 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 669 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 453 | 81 |
| Metformin Hcl | Metformin Hcl | 393 | 58 |
| Meloxicam | Meloxicam | 379 | 62 |
| Omeprazole | Omeprazole | 367 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 364 | 44 |
| Lisinopril | Lisinopril | 364 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 40 |
| Gabapentin | Gabapentin | 262 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 261 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 31 |
| Potassium Chloride | Potassium Chloride | 199 | 37 |
| Losartan Potassium | Losartan Potassium | 195 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 162 | 25 |
| Atenolol | Atenolol | 160 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 151 | 25 |
| Trazodone Hcl | Trazodone Hcl | 141 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 19 |
| Tramadol Hcl | Tramadol Hcl | 136 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 116 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 110 | 20 |
| Eliquis | Apixaban | 106 | 14 |
| Warfarin Sodium | Warfarin Sodium | 105 | 13 |
| Trulicity | Dulaglutide | 103 | 13 |
| Valsartan | Valsartan | 102 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 13 |
| Alprazolam | Alprazolam | 95 | 14 |
| Prednisone | Prednisone | 93 | 63 |
| Carvedilol | Carvedilol | 92 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 22 |
| Simvastatin | Simvastatin | 88 | 16 |
| Donepezil Hcl | Donepezil Hcl | 84 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | suppressed |
| Furosemide | Furosemide | 80 | 17 |
| Allopurinol | Allopurinol | 77 | 13 |
| Ezetimibe | Ezetimibe | 77 | 18 |
| Glipizide | Glipizide | 77 | 18 |
| Bumetanide | Bumetanide | 69 | 14 |
| Famotidine | Famotidine | 67 | 15 |
| Mirtazapine | Mirtazapine | 65 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 12 |
| Ozempic | Semaglutide | 63 | 12 |
| Januvia | Sitagliptin Phosphate | 62 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | suppressed |
| Celecoxib | Celecoxib | 59 | suppressed |
| Glipizide Er | Glipizide | 58 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 58 | 11 |
| Farxiga | Dapagliflozin Propanediol | 55 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 11 |
| Sertraline Hcl | Sertraline Hcl | 55 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | suppressed |
| Finasteride | Finasteride | 52 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 13 |
| Eszopiclone | Eszopiclone | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Risperidone | Risperidone | 50 | suppressed |
| Verapamil Er | Verapamil Hcl | 49 | suppressed |
| Nitroglycerin | Nitroglycerin | 48 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Fluconazole | Fluconazole | 40 | 13 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Torsemide | Torsemide | 36 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Nystatin | Nystatin | 26 | 12 |
| Primidone | Primidone | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 12 |
| Diazepam | Diazepam | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 18 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Fluorouracil | Fluorouracil | 13 | 13 |
| Lactulose | Lactulose | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $265.52 · 16 records | PFIZER INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, GVOKE HYPOPEN, JADA SYSTEM, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error